DiscoveRx Corp. & Jubilant Biosys Limited Announce Co-Marketing Agreement for Screening Services

BANGALORE, India, January 11 - Jubilant Biosys Limited, based in Bangalore, an integrated
Drug Discovery and Development solution provider, a subsidiary of Jubilant
Organosys Ltd, headquartered in Noida, announced today that it has entered
into a co-marketing agreement to provide screening solutions, with DiscoveRx
Corporation (Fermont, USA), a premier provider of innovative cell based assay
solutions for GPCR, Kinases, NHR and Proteases.

This agreement allows Jubilant access to DiscoveRx
PathHunter(TM) and cAMPHunter(TM) cell lines and proprietary EFC
chemiluminescent detection technology to perform screening on behalf of
Jubilant's customers. The agreement also enables DiscoveRx to expand its
platform technology to offer screening solutions from India.

DiscoveRx's PathHunter(TM) ss-Arrestin and HitHunter(TM) cAMP
assays are homogeneous chemiluminescent assays which are rapidly becoming
GPCR screening platform of choice for screening and profiling applications.
Jubilant's demonstrated capabilities in discovery research state of the art
medicinal chemistry, modeling, structural biology and screening facilities
including High Throughput screening facility supported by automated compound
management and visualization tools coupled with the DiscoveRx award winning
assay platform offers global pharmaceutical companies access to cost
effective screening and lead generation services that will enable and
accelerate global drug discovery efforts.

Commenting on the Collaboration, Dr. Kailash Swarna, COO,
Global Drug Discovery, at Jubilant Biosys said:

"We are pleased to announce this agreement with DiscoveRx, and
look forward to the prospect of providing value to our customers using
DiscoveRx PathHunter(TM) and HitHunter(TM) technologies. This partnership
continues to demonstrate Jubilant's mission to partner with leading
technology providers that provide access to cutting edge and innovative
solutions to accelerate global drug discovery efforts with our
collaborators."

Pyare Khanna, President and CEO, DiscoveRx Corporation says,

"DiscoveRx constantly strives to provide our truly innovative
solutions to screening community. We are determined to help expedite the drug
discovery processes and are delighted with this relationship with Jubilant.
Our customers require an easy access to our innovative product portfolio and
such partnerships will add value to our efforts of bringing industry leading
portfolio of PathHunter(TM) and HitHunter(TM) GPCR assays to a broader
audience."

About DiscoveRx Corporation

Founded in 2000, DiscoveRx is a privately held, venture-backed company
headquartered in Fremont, California, with an additional office in
Birmingham, England. The Company pioneered the use of B-galactosidase enzyme
fragment complementation in biochemical and cell based assays for discovery
research, and holds extensive intellectual property in this area. DiscoveRx
is dedicated to the development and commercialization of innovative solutions
to study GPCRs, Kinases and other major drug target classes, and many of
their innovative products have been widely adopted in pharmaceutical and
biotech drug screening laboratories worldwide. The Company is also a
recipient of two Frost and Sullivan 2008 awards: Award for Innovation in
North American Healthcare Market as well as a European Product Line Strategy
Award for it's GPCR Cell Based assay portfolio. For more information on
DiscoveRx products, please visit www.discoverx.com.

About Jubilant Biosys:

Jubilant Biosys Ltd., a subsidiary of Jubilant Organsys Ltd.,
provides integrated drug discovery and development solutions to the global
pharmaceutical industry. Jubilant Biosys has an integrated state of the art
facility in Bangalore. The Center houses over 450 scientists specializing in
multiple disciplines to include Discovery biology, medicinal chemistry,
structural biology, pharmacology, toxicology, pharmacy chem., molecular
modeling, crystallography and information technology supporting discovery
efforts. For more information please visit: www.jubilantbiosys.com

    Contacts:

    DiscoveRx Corporation
    Sailaja Kuchibhatla
    Sr. VP Business Development
    DiscoveRx Corp.
    skuchibhatla@discoverx.com
    +1-510-979-1415 ext. 104

    Jubilant Biosys Ltd.
    Esha Kakkar
    Executive - Corporate Planning
    Jubilant Biosys Ltd.
    Ph: +91-80-66628683
    esha_kakkar@jubilantbiosys.com

Contacts: DiscoveRx Corporation, Sailaja Kuchibhatla, Sr. VP Business Development, DiscoveRx Corp. skuchibhatla at discoverx.com; +1-510-979-1415 ext. 104, Jubilant Biosys Ltd. Esha Kakkar, Executive - Corporate Planning, Jubilant Biosys Ltd. Ph: +91-80-66628683, esha_kakkar at jubilantbiosys.com